Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

UnitedHealthcare Will Share The Savings: Point-Of-Sale Rebates Coming In 2019

Biggest benefit to manufacturers from the insurer's upcoming program may be relieving public pressure on list prices.

Pricing Debate Policy Private Payers

Latest From Pricing Debate

DTC And The Art Of Selling An Establishment Pricing Plan To A Populist President

The most surprising proposal coming out the Rose Garden drug pricing event was a call for disclosure of prices in DTC ads. As a policy idea, it may be a dud – but that doesn’t mean it isn’t a critical element of the plan.

Advertising, Marketing & Sales Pricing Debate

US Drug Pricing Reform: No More Medicare 'Gravy Train,' Azar Tells Pharma

HHS secretary urges serious proposals from biopharma on enhancing price negotiation in Medicare Parts D and B, promising action from the Administration whether the industry cooperates or not.

Pricing Debate Medicare

Mehta Analysis: Trump Pricing Tempest In A Teapot Is An Opportunity For Biopharma Leaders

President Trump's much anticipated pronouncements on drug pricing reform leave a lot to be clarified. Biopharma companies and their leaders should grasp the opportunity to lead from the front and propose tangible and transformative actions that deliver benefits for all stakeholders, writes Viren Mehta, founding partner of Mehta Partners LLC.

Pricing Debate Strategy

Part B Drug Competitive Bidding Program Revival: Vendor Request Coming Soon

Distributors, specialty pharmacies and PBMs are in a better position now to act as vendors then they were a decade ago, when Medicare unsuccessfully tried to implement a Medicare Part B prescription drug competitive acquisition program, HHS Secretary Azar points out.

Pricing Debate Medicare

Pharma’s Blame-The-Middleman Strategy Pays Off – For Now

Success of drug industry’s campaign to highlight role of 'middlemen' in the supply chain was never more clear than during President Trump’s Rose Garden drug pricing event. But what happens now that the attention is turned squarely back on manufacturers?

Pricing Debate Pharmacy Benefit Management

Pricing Positives From Trump Plan Include Potential 340B Changes, Value-Based Contracts

Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.

Pricing Debate Policy

REMS Website Will Name, Not Shame, Potential Abusers – Gottlieb

US FDA will list number of inquiries about acquiring samples for generic drug development, and also whether FDA sends letters to brand companies telling them it is safe to provide the generic sponsor with the samples. 
Risk Management Generic Drugs

IL Inhibitors Clear Path To Better Psoriasis Treatment

Advances in psoriasis therapy in the last few years have revolutionized the treatment of the condition and a high percentage of patients are achieving clear or nearly clear skin, thanks to drugs targeting interleukin-17, 12 and 23. What's more, a number of payers are increasingly recognizing these new treatments as cost-effective. Scrip's infographic provides a snapshot.

Innovation Dermatology

Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan

Bringing the hammer down on biopharma, HHS Secretary Azar says department could use demonstration projects to switch drugs from Medicare Part B to Part D.
Medicare Pricing Debate
See All
UsernamePublicRestriction

Register